News

April 3, 2024

The company announced an oversubscribed recent funding boost toward the preclinical development of its HHLA2 and IL18BP programs

July 24, 2023

The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients.

May 27, 2022

Orthogon Therapeutics is developing first-in-class anti-infective small molecule drugs using biophysics- and structure-based drug design to optimize compounds that target difficult-to-drug proteins. The company’s initial focus is on treating BK and JC polyomavirus infections in transplant patients.

May 6, 2022

Russia’s invasion of Ukraine has triggered catastrophic human suffering and consequently the most widespread economic boycott of a belligerent nation in modern history. The fallout will have major consequences for the biotech and pharmaceutical industries, and the medical innovations they drive forward.

November 15, 2021

CANTON, Mass.–(BUSINESS WIRE)–Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has appointed Dr. Marie Lindner as an independent director to its board of directors.

November 8, 2021

Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has raised an $8M round from a leading syndicate of US based healthcare Angels to advance its pipeline of first-in-class drug assets. This financing brings the total investment to date in the Company to $12.5M.